The Pharmaceutical Journal
Vol 277 No 7426 p574
11 November 2006

This article
Reprint   Photocopy

PDF 50K, Acrobat Reader

· Pharmacy in Spain
· Controlled drugs
· Community pharmacy
· Prescribing
· Medicines use reviews
· Safety (2)
· Supermarket pharmacy
· The profession (4)
· The Council
· Statutory Committee
· Retention fee
· Section 60 Order
· The Society
· Pfizer products

Letters to the Editor

Pfizer products

Pushing ahead with simvastatin

From Dr B. P. Curwain, MRPharmS

Barinderjit Shoker (PJ, 28 October, p513) suggests Pfizer has opened a can of worms. Worms as we know are actually useful creatures. He says “in certain primary care trusts the use of simvastatin is more encouraged as first-line treatment”. In the interests of NHS finances, I would hope that all PCTs are now pushing ahead with this since there are many millions of pounds of taxpayers’ money to be saved. As we have shown in the New Forest, where we have moved from less than 50 per cent to over 75 per cent simvastatin, it can be done.  Perhaps community pharmacists can help their local PCTs by talking to their prescribers about this?

Brian Curwain
Medicines Management Team
Hampshire Primary Care Trust

Send your letter to The Editor

Previous Topic (The Society)